Real-life management of neovascular age-related macular degeneration (nAMD) in France: a nationwide observational study using retrospective claims data
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Aims Intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy is standard care for neovascular age-related macular degeneration (nAMD), but the recommended monthly injection regimen is burdensome. Evidence suggests low injection/monitoring frequencies in clinical practice and suboptimal vision outcomes. This observational cohort study uses administrative claims data from the French national healthcare system to assess anti-VEGF treatment patterns and nAMD-specific healthcare resource demands and costs.Patients and methods nAMD patients ≥50 years initiating intravitreal ranibizumab, aflibercept or bevacizumab treatment (2014‒2015), and propensity score-matched non-nAMD patients (controls), were identified from the Echantillon Généraliste de Bénéficiaires database. Outcomes of interest included anti-VEGF treatment patterns, and healthcare resource utilization and associated costs of patients vis-à-vis controls over 24 months.Results Study patients (n = 355) received (mean) 5.2 and 2.4 anti-VEGF injections over 0‒12 and 12‒24 months, respectively. Most patients (79.0%) remained on their initial anti-VEGF agent; among treatment switchers, the most common transition was from ranibizumab to aflibercept. During follow-up, nAMD patients were more likely than controls to require ophthalmology visits (99.7% vs. 44.8%), ocular procedures (optical coherence tomography/angiography/fundoscopy) (96.9% vs. 27.2%), cataract surgery (13.0% vs. 6.7%), and medical transports (38.0% vs. 31.9%). Mean numbers of ophthalmology visits (25.1 vs. 1.2) and medical transports (6.0 vs. 3.5) were higher (p<.01) among nAMD patients. Total reimbursed costs were two-fold higher for nAMD patients than controls (mean €16,799 vs. €8,255) due to higher treatment costs (€6,847 vs. €1,156), medical fees (€1,858 vs. €295), hospital fees (€6,396 vs. €5,235), and transport costs (€358 vs. €259). Excess total healthcare cost was (mean) €5,279 and €7,918 over the first 12 and 24 months of treatment, respectively.Conclusions Current intravitreal anti-VEGF treatment and monitoring requirements place a considerable economic burden on the French healthcare system. New intravitreal therapies with extended dosing intervals and predictable efficacy might reduce demand for ophthalmology services.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“On the other hand, a significant number of conditions, including nAMD, DR, DMO and macular oedema secondary to RVO and mCNV, are conditions for which anti-VEGF based treatments are indicated, but only a minority of this study’s results included costs of anti-VEGF injections (n = 9 [34–36, 48–50, 54–56]).”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [36]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Validation of a combined comorbidity index
Charlson, M., Szatrowski, T. P., Peterson, J., & Gold, J. (1994) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)90129-5 · Cited by 6,587 · cited 6×
“CCI was based on 19 comorbidities weighted for severity and was adjusted for age30.”
MethodInfluentialRanibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522 · cited 2×
“It is also apparent from our analysis that despite regular patient follow-up (as reflected in a mean of 15.6 and 10.2 outpatient ophthalmology visits in Years 1 and 2, respectively) and regular monitoring of disease activity (mean 8.1 and 6.0 OCT examinations during Years 1 and 2, respectively), study patients were tr…”
BackgroundInfluentialRanibizumab and bevacizumab for neovascular age-related macular degeneration
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102673 · Cited by 2,669
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
Heier, J. S., Brown, D. M., Chong, V., Korobelnik, J.-F., Kaiser, P. K., Nguyen, Q. D., Kirchhof, B., Ho, A., Ogura, Y., Yancopoulos, G. D., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.09.006 · Cited by 2,485 · cited 2×
“It is also apparent from our analysis that despite regular patient follow-up (as reflected in a mean of 15.6 and 10.2 outpatient ophthalmology visits in Years 1 and 2, respectively) and regular monitoring of disease activity (mean 8.1 and 6.0 OCT examinations during Years 1 and 2, respectively), study patients were tr…”
BackgroundInfluentialSelf-citationAge-related macular degeneration
Mitchell, P., Liew, G., Gopinath, B., & Wong, T. Y. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31550-2 · Cited by 1,511
Holz, F. G., Tadayoni, R., Beatty, S., Berger, A., Cereda, M. G., Cortez, R., Hoyng, C. B., Hykin, P., Staurenghi, G., Heldner, S., et al. (2015) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305327 · Cited by 615 · cited 4×
“Consistent with previous reports [15, 18, 33], our analysis of reimbursement claims indicates that ranibizumab was the most widely used anti-VEGF agent for treatment of incident nAMD in French clinical practice during 2014‒2017, followed by aflibercept, with bevacizumab used only rarely, and that the vast majority of…”
BackgroundResultInfluentialBezin, J., Duong, M., Lassalle, R., Droz, C., Pariente, A., Blin, P., & Moore, N. (2017) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4233 · Cited by 584 · cited 4×
“8% of the French population, making it one of the world’s largest and most representative databases of its type [27, 28].”
BackgroundInfluentialBusbee, B. G., Ho, A. C., Brown, D. M., Heier, J. S., Suñer, I. J., Li, Z., Rubio, R. G., & Lai, P. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2012.10.014 · Cited by 500
Prevalence of Age-Related Macular Degeneration in Europe
Colijn, J. M., Buitendijk, G. H. S., Prokofyeva, E., Alves, D., Cachulo, M. L., Khawaja, A. P., Cougnard-Gregoire, A., Merle, B. M. J., Korb, C., Erke, M. G., et al. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2017.05.035 · Cited by 486
Self-citationBannay, A., Chaignot, C., Blotière, P.-O., Basson, M., Weill, A., Ricordeau, P., & Alla, F. (2016) · Medical Care · doi:10.1097/mlr.0000000000000471 · Cited by 484 · cited 1×
“CCI was based on 19 comorbidities weighted for severity, and was adjusted for age [30].”
Method
Research works printed but not linked: 3
- Brown GC, 2005, Trans Am Ophthalmol Soc, 103, 173
- Agarwal A, 2015, Clin Ophthalmol, 9, 1001
- Rakic JM, 2013, Clin Ophthalmol, 7, 1849
Cited by
Creuzot-Garcher, C. P., Srour, M., Baudin, F., Dot, C., Nghiem‐Buffet, S., Girmens, J., Collin, C., Ponthieux, A., & Delcourt, C. (2023) · Ophthalmology and Therapy · doi:10.1007/s40123-023-00772-3 · Cited by 6
“Our results suggest that nAMD patients in the real-world setting were dosed less frequently than those in the RCTs whose results supported anti-VEGF approvals, and less frequently than recommended in treatment guidelines, similarly to the results of other real-world studies showing under-treatment [5, 15, 16, 22, 23].”
ResultSelf-citationOhnaka, M., Sakurada, Y., Hayashi, A., Kadonosono, K., Ohno, H., Mori, R., Matsumoto, H., Nagamori, I., Murata, Y., Maio‐Twofoot, T., et al. (2025) · Ophthalmology and Therapy · doi:10.1007/s40123-025-01159-2 · Cited by 6
Schuster, A. K.-G., Wolfram, C., Hudde, T., Klatt, A., Schnegelsberg, B., Midani-Oezkan, H., Ross, M., Ziemssen, F., & Pfeiffer, N. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12123881 · Cited by 4
“The most common treatment regimens in ALBATROS were ‘’treat and extend” or modifications of this regimen, such as ‘’monitor and extend,” and confirming observations made in other real-world studies [9,10].”
BackgroundResultCarga económica de la degeneración macular neovascular y el edema macular diabético en Colombia
Gil-Rojas, Y., Amaya-Granados, D., Sardi, C., Robles, A., & Hernández, F. (2023) · Revista Sociedad Colombiana de Oftalmología · doi:10.24875/rsco.23000015 · Cited by 2
Traitement topique de la dégénérescence maculaire liée à l’âge: Où en sommes-nous ?
Pierre, M., Lamaa, D., Fabre, M., Ronco, C., Benhida, R., Demange, L., & Charrueau, C. (2023) · médecine/sciences · doi:10.1051/medsci/2023177 · Cited by 5
Metadata
- Authors
- Korobelnik, J.-F., Delcourt, C., Creuzot-Garcher, C., Melaine, A., Chassetuillier, J., Lejeune, A., Bénard, S., & Dupont-Benjamin, L.
- Affiliations
- Université de Bordeaux (FR)
- CHU Dijon Bourgogne (FR)
- Stève Consultants, Oullins, France
- Allergan (France) (FR)
- Allergan, an AbbVie company, Courbevoie, France
- ORCID
- Venue
- Journal of Medical Economics
- Publisher
- Informa UK Limited
- Published
- 2021-01-01
- Volume
- 24
- Issue
- 1
- Pages
- 1087-1097
- ISSN
- 1369-6998 (ISSN-L)
- 1941-837X
- OpenAlex
- W3195037965
- Cited by
- 9
- References
- 48
- Citations by year
- 2026: 3 · 2025: 2 · 2023: 4
- FWCI
- 0.90
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- Locations
- Journal of Medical Economics (publishedVersion, other-oa)
- PubMed (publishedVersion)
- HAL (submittedVersion, cc-by-nc-nd)
- Oskar-Bordeaux (Universite de Bordeaux) (submittedVersion, cc-by-nc-nd)
- Funders
- Allergan (an AbbVie company), Irvine, CA, USA
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Keywords
- neovascular age-related macular degeneration, anti-VEGF therapy, intravitreal injection, treatment patterns, healthcare resource utilization, health care costs, ranibizumab, aflibercept, bevacizumab, treatment switching, cataract surgery, France, administrative claims data, real-world practice
- MeSH terms
- Ranibizumab, Humans, Macular Degeneration, Recombinant Fusion Proteins, Retrospective Studies, Treatment Outcome, Angiogenesis Inhibitors, Receptors, Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factor A, Wet Macular Degeneration, Intravitreal Injections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Real-life management of neovascular age-related macular degeneration (nAMD) in France: a nationwide observational study using retrospective claims data. https://app.cochat.ai/papers/10.1080/13696998.2021.1971416
- The paper
- Korobelnik, J.-F., Delcourt, C., Creuzot-Garcher, C., Melaine, A., Chassetuillier, J., Lejeune, A., Bénard, S., & Dupont-Benjamin, L. (2021). Real-life management of neovascular age-related macular degeneration (nAMD) in France: a nationwide observational study using retrospective claims data. Journal of Medical Economics. https://doi.org/10.1080/13696998.2021.1971416
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.